Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Momenta Pharmaceuticals, Inc. (MNTA) is “One to Watch”

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two […]

Akebia Therapeutics (AKBA) ‘Buy’ Rating Reiterated with Higher Stock Price Target of $18

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharma company that focuses on the development of innovative treatments for chronic kidney disease-related anemia, is maintaining its ‘Buy’ rating, with a recommended stock price target of $18 compared to the current $8.90, according to an Aegis Capital Corp. report (http://dtn.fm/2z8XE) released on November 15. The rating and suggested […]

National Waste Management Holdings, Inc. (NWMH) Plans Further Growth with Targeted Acquisitions

In its latest quarterly report (10-Q), National Waste Management Holdings (OTC: NWMH), a solid waste management company headquartered in central Florida, demonstrated impressive growth. The company is currently running at full speed to achieve its stated objective of becoming a leading national solid waste company through organic growth and acquisitions. Revenues for the third quarter […]

Citius Pharmaceuticals, Inc. (CTXR) is “One to Watch”

Citius Pharmaceuticals, Inc. (OTCQB: CTXR), a specialty biopharmaceutical company that develops and commercializes therapeutics products, has been a topic of conversation among analysts since the initiation of its phase III clinical trial of Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters and treat bloodstream infections that stem from catheters. This phase […]

Agora Holdings, Inc. (AGHI) – Framing the Narrative for Social Brands

The human imagination is capable of incredibly brilliant creations, including the technological innovations that Agora Holdings, Inc. (OTC: AGHI) is developing to create tools that can help people and companies save time and improve performance, all while publishing more content. Agora Holdings, together with subsidiary Geegle Media and its affiliates, is a global family entertainment […]

Zogenix, Inc. (ZGNX) Develops Orphan Drug for Dravet Syndrome Epilepsy

Zogenix, Inc (NASDAQ: ZGNX) is a clinical stage pharmaceutical company committed to the development and commercialization of therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases. The company’s lead product candidate, ZX008, is currently being evaluated for the treatment of one such disease – Dravet Syndrome. Despite […]

Matinas BioPharma Holdings, Inc. (MTNB) is “One to Watch”

Matinas BioPharma Holdings, Inc. (OTCQB: MTNB), is a biopharmaceutical company still in its clinical stages, focused on identifying and developing treatments for fungal and bacterial infections. Founded in 2012, the company’s goal is to change the way in which potent medicines are delivered and administered, with the aim of giving both physicians and patients better, […]

 

From Our Blog

TruGolf Holdings Inc. (NASDAQ: TRUG) Completes Polymath Acquisition, Offering Expansion into Institutional Tokenization

October 20, 2026

TruGolf Holdings (NASDAQ: TRUG), a producer of advanced golf simulation systems for home or entertainment venues, has completed its acquisition of Polymath Research Inc., bringing a blockchain platform designed for regulated financial assets into the publicly traded golf technology company’s business. Announced October 9, the transaction combines TruGolf’s golf simulation hardware and software operations with […]

Rotate your device 90° to view site.